Why can’t the U.S. control prescription drug pricing as they do in the U.K., where per-capita spending is less than half our level?
In a capitalist democracy, many parties — the drug companies, medical associations, consumer groups — get to lobby their points of view. Is the problem intractable, or just an exercise in chaos?
Our three guests have written a book about the problem, “The Right Price: A value-based prescription for drug costs.” And although they don’t have a definitive answer, they do offer recommendations, interesting observations, and a way forward.
Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R&D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more
An obscure think tank in Boston is getting drug companies to lower their prices – using something called a QALY. WSJ’s Denise Roland explains what a QALY is, and why it’s controversial.
Boomers Daily 